FOLH1 and prostate cancer: Overall, the in vivo biodistribution demonstrates that both [99mTcO2(DPAn-PSMAt)2]+ and [99mTcO2(DPMEP-PSMAt)2]+ are useful SPECT or γ-scintigraphy imaging agents for PSMA expression in prostate cancer.